Benzinga | Jan 18, 2022 07:22AM EST

Barclays Upgrades CytomX Therapeutics to Overweight, Announces $7 Price Target

Barclays analyst Peter Lawson upgrades CytomX Therapeutics (NASDAQ:CTMX) from Underweight to Overweight and announces $7 price target.